Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · IEX Real-Time Price · USD
127.39
+3.14 (2.53%)
At close: Apr 25, 2024, 4:00 PM
124.26
-3.13 (-2.46%)
After-hours: Apr 25, 2024, 7:51 PM EDT
Sarepta Therapeutics Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for SRPT stock have an average target of 160.82, with a low estimate of 109 and a high estimate of 224. The average target predicts an increase of 26.24% from the current stock price of 127.39.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 1, 2024.
Analyst Ratings
The average analyst rating for SRPT stock from 17 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 7 | 7 | 7 | 7 |
| Buy | 10 | 9 | 9 | 9 | 8 | 7 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 20 | 20 | 19 | 19 | 18 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $164 → $167 | Strong Buy | Maintains | $164 → $167 | +31.09% | Mar 1, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates $128 | Hold | Reiterates | $128 | +0.48% | Feb 29, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $151 → $157 | Buy | Maintains | $151 → $157 | +23.24% | Feb 29, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $160 → $172 | Strong Buy | Maintains | $160 → $172 | +35.02% | Feb 29, 2024 |
| Barclays | Barclays | Buy Maintains $141 → $185 | Buy | Maintains | $141 → $185 | +45.22% | Feb 29, 2024 |
Financial Forecast
Revenue This Year
1.90B
from 1.24B
Increased by 52.90%
Revenue Next Year
2.97B
from 1.90B
Increased by 56.34%
EPS This Year
2.50
from -5.80
EPS Next Year
11.26
from 2.50
Increased by 350.26%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.5B | 5.0B | 5.7B | 5.9B | 6.1B |
| Avg | 1.9B | 3.0B | 3.6B | 3.6B | 3.7B |
| Low | 1.5B | 1.5B | 1.9B | 1.8B | 2.0B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 104.7% | 160.5% | 92.3% | 61.6% | 67.9% |
| Avg | 52.9% | 56.3% | 22.7% | -0.6% | 2.0% |
| Low | 19.4% | -22.7% | -36.6% | -50.7% | -45.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 7.11 | 25.48 | 28.31 | 17.72 | 8.48 |
| Avg | 2.50 | 11.26 | 13.40 | 12.18 | 8.24 |
| Low | -1.80 | -1.61 | 1.15 | 6.86 | 7.92 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 919.0% | 151.4% | 32.3% | -30.3% |
| Avg | - | 350.3% | 19.0% | -9.1% | -32.3% |
| Low | - | - | -89.8% | -48.8% | -35.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.